Skip to main content

Table 1 Prognostic factors for overall survival identified by univariate and multivariate analyses (n = 139)

From: Impact of low skeletal muscle mass index and perioperative blood transfusion on the prognosis for HCC following curative resection

    

Univariate

Multivariate

Variables

n (%)

3-year survival

5-year survival

P-value

HR

95% CI

P-value

Male sex

110 (79%)

65.4%

56.7%

0.258

   

Female sex

29 (21%)

88.5%

68.5%

    

Age (years)

  ≤ 80

109 (78%)

74.1%

66.8%

0.002

1.979

1.050–3.732

0.035

  > 80

30 (22%)

54.1%

33.7%

    

BMI (kg/m2)

  > 25

34 (25%)

74.4%

63.0%

0.441

   

  ≤ 25

105 (75%)

68.7%

58.1%

    

ALBI

 grade III

30 (22%)

64.2%

55.0%

0.677

   

  < grade III

109 (78%)

71.4%

59.6%

    

HBV

 (+)

27 (19%)

78.3%

78.3%

0.027

1.681

1.037–2.726

0.035

 (−)

112 (81%)

67.9%

52.7%

    

HCV

 (+)

70 (50%)

71.5%

59.4%

0.668

   

 (−)

69 (50%)

68.0%

58.8%

    

DM

 (+)

29 (21%)

75.3%

58.6%

0.582

   

 (−)

110 (79%)

68.6%

58.6%

    

NLR

  ≥ 4

13 (9%)

52.6%

52.6%

0.257

   

  < 4

126 (91%)

71.3%

60.0%

    

PLT (×104/μL)

 normal (13–35)

97 (70%)

73.4%

60.7%

0.582

   

 abnormal

42 (30%)

63.1%

55.4%

    

Hb (g/dL)

 normal (13.5–15.8)

95 (68%)

74.2%

63.7%

0.094

   

 abnormal

44 (32%)

61.2%

50.1%

    

PT (%)

 normal (70–130)

125 (90%)

72.3%

60.4%

0.172

   

 abnormal

14 (10%)

46.2%

46.2%

    

AST (U/L)

 normal (13–33)

71 (51%)

78.6%

59.9%

0.086

   

 abnormal

68 (49%)

61.1%

56.5%

    

ALT (U/L)

 normal (8–42)

100 (72%)

73.2%

59.7%

0.298

   

 abnormal

39 (28%)

61.8%

57.0%

    

CHE (g/dL)

 normal (229–521)

77 (55%)

74.6%

64.0%

0.110

   

 abnormal

62 (45%)

63.6%

52.6%

    

Alb (g/dL)

 normal (4.0–5.0)

115 (83%)

72.2%

60.3%

0.165

   

 abnormal

24 (17%)

58.4%

51.9%

    

T-chol (mg/dL)

 normal (128–219)

118 (85%)

71.7%

59.1%

0.732

   

 abnormal

20 (14%)

66.9%

66.9%

    

PIVKA-II (mAU/mL)

 normal (< 40)

62 (45%)

81.0%

74.7%

0.009

1.852

0.940–3.649

0.075

 abnormal

77 (55%)

60.8%

45.7%

    

AFP (ng/mL)

 normal (> 10)

68 (49%)

73.8%

66.9%

0.126

   

 abnormal

68 (49%)

66.2%

51.4%

    

Tumor number

 solitary

113 (81%)

70.6%

65.5%

0.167

   

 multiple

26 (19%)

67.9%

37.0%

    

Tumor size

 3 cm <

71 (51%)

68.0%

59.5%

0.185

   

  ≤ 3 cm

54 (39%)

78.5%

71.5%

    

Poor differentiation

20 (14%)

73.7%

48.4%

0.545

   

Others (well, moderately)

119 (86%)

69.2%

61.1%

    

IM

 (+)

19 (14%)

34.1%

22.7%

< 0.001

3.675

1.848–7.308

< 0.001

 (−)

120 (86%)

77.1%

66.0%

    

Vp

 (+)

26 (19%)

49.6%

42.5%

0.009

1.700

0.940–3.649

0.130

 (−)

113 (81%)

74.6%

62.8%

    

Low SMI

86 (62%)

63.6%

52.4%

0.039

2.006

1.012–3.974

0.046

High SMI

53 (38%)

80.9%

70.5%

    

Blood transfusion

 (+)

22 (16%)

40.0%

30.0%

0.002

2.012

1.001–4.045

0.050

 (−)

117 (84%)

75.5%

64.3%

    
  1. Variables in bold are statistically significant (P < 0.05)
  2. Abbreviations: BMI Body mass index, ALBI albumin-bilirubin, HBV hepatitis type B, HCV hepatitis type C, DM diabetes mellitus, NLR neutrophil-to-lymphocyte ratio, PLT platelets, Hb hemoglobin, PT prothrombin time, AST aspartate aminotransferase, ALT alanine aminotransferase, CHE cholinesterase, Alb albumin, T-chol total-cholesterol, PIVKAII protein induced by vitamin K absence or antagonist-II, AFP α-fetoprotein, IM intrahepatic metastasis, VP portal vain invasion, SMI skeletal muscle mass index
Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us